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Increasing the threshold for patient global 
assessment in defining remission may have a 
different impact in patients with early and 
established rheumatoid arthritis
A significant proportion of patients with rheumatoid arthritis 
(RA) misses the target of disease remission solely because of the 
patient global assessment of disease activity (PGA) exceeding 
the cut- off of 1.1–5 As PGA may also reflect non- inflammatory 
symptoms, its inclusion as a driver of intensification of immu-
nosuppressive therapy is currently been questioned.6 Complete 
omission of the patients’ perspective, however, impairs func-
tional outcomes and the ability to discriminate effective treat-
ments from placebo.7 As such, different thresholds for the PGA 
are being tested, with a recent proposal from randomised clinical 
trials suggesting a suitable cut- off of 2.8
Here, we evaluated the performance of modifying the Boolean 
definition of remission9 by increasing the cut- off of the PGA to 
28 in real life. Data were retrieved from 826 consecutive patients 
from two University Hospitals with an observation period of 12 
months. Five hundred and thirty- five were patients with early 
RA (median (IQR) symptoms’ duration 16 [9–28] weeks) started 
on methotrexate aimed at low disease activity.10 Two hundred 
and ninety- one were established patients with RA (median (IQR) 
duration 6.7 [3.4–13.6] years) started on a biological drug (a 
tumour necrosis factor antagonist in 79.4% of the cases). In 
early RA, the rates of remission following PGA modification 
only slightly increased of +4.1% at 6 months and +4.3% at 
12 months. Within remitters according to the Simplified Disease 
Activity Index (SDAI), simultaneous Boolean remitters increased 
from 65.7% at 6 months and 64.7% at 12 months with the orig-
inal definition to 81.8% and 85.7% with the modified defini-
tion. However, modified Boolean remitters (original Boolean 
remitters excluded) were in SDAI remission in fewer cases 
compared with original Boolean remitters (40.9% vs 97.1% 
and 57.1% vs 96.7% at 6 and 12 months). As such, the concor-
dance with SDAI remission was lower for modified compared 
with original Boolean remission at both time points (κ statistics 
0.35, 95% CI 0.11 to 0.58 vs 0.74, 95% CI 0.67 to 0.82 and 
0.52, 95% CI 0.28 to 0.75 vs 0.71, 95% CI 0.64 to 0.78). In 
contrast, in established RA, the increase in the remission rate was 
more pronounced (+7.3% and +12.5% at 6 and 12 months), 
and concordance with SDAI remission was higher compared 
with early RA (κ statistics 0.63, 95% CI 0.42 to 0.84 and 0.65, 
95% CI 0.46 to 0.84 at the two time points). Patients in modified 
Boolean remission also showed different disease activity char-
acteristics and functional outcomes in relation to disease dura-
tion (table 1). Indeed, in early RA, modified Boolean remitters 
at 6 months had significantly higher levels of C reactive protein 
(CRP) compared with original Boolean remitters. Furthermore, 
their Health Assessment Questionnaire (HAQ) at 12 months 
worsened of a clinically significant mean (SD) of 0.24 (0.31) 
points compared with functional stability in original Boolean 
remitters, and an HAQ ≤0.5 was observed in fewer cases. In 
contrast, in established RA, CRP levels, HAQ variations and the 
rate of good functional outcome (HAQ ≤0.5) at 12 months were 
comparable between modified and original Boolean remitters.
The inclusion of patients from a real- life clinical setting, with 
different disease duration, activity and treatment protocols 
hampers any comparison with published studies,8 and our obser-
vations need confirmation in independent cohorts. However, 
our data suggest that a cut- off of the PGA of 2 increases the 
rates of remission without impacting on outcomes in patients 
with established RA. In contrast, in early disease, before changes 
in pain processing mechanisms have occurred,11 the PGA may 
more strictly collect information on inflammatory- related symp-
toms, and even small increases of its cut- off may affect functional 
outcomes. Better understanding of the relationship between 
patient- reported outcomes and disease activity in the various 
phases of RA may thus be needed before introducing definitive 
changes in the current definition of remission.
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Table 1 Comparison of disease characteristics and functional 
outcomes according to the original and the modified definition of 
remission
Original Boolean 
remission
Modified Boolean 
remission P value
6 months
Early RA     
  SJC28 0.5 (0.6) 0.6 (0.5) 0.77
  TJC28 0.1 (0.4) 0.4 (0.7) 0.08
  VAS pain 0–100 3.9 (7.7) 16.7 (7.2) <0.001
  HAQ 0–3 0.11 (0.25) 0.18 (0.30) 0.26
  ESR, mm/1 h 13.6 (10) 15.8 (9.9) 0.41
  CRP, mg/dL 0.26 (0.22) 0.43 (0.32) 0.01
Established RA     
  SJC28 0.1 (0.2) 0.2 (0.6) 0.21
  TJC28 0.2 (0.4) 0.3 (0.5) 0.34
  VAS pain 0–100 5.8 (6.1) 13.6 (6.8) <0.001
  HAQ 0–3 0.16 (0.27) 0.35 (0.29) 0.007
  ESR, mm/1 h 15.7 (12) 19 (13.5) 0.27
  CRP, mg/dL 0.32 (0.23) 0.31 (0.25) 0.80
Functional outcomes at 12 months
Early RA     
  HAQ variation from 6 to 12 
months
0.02 (0.34) paired 
t- test p=0.61
0.24 (0.31) paired t- test 
p=0.004
0.02
  HAQ ≤0.5 93% 72.2% 0.05
Established RA     
  HAQ variation from 6 to 12 
months
0.02 (0.26) paired 
t- test p=0.56
−0.09 (0.29) paired 
t- test p=0.20
0.12
  HAQ ≤0.5 88.1% 88.9% 0.75
Data are reported as means and SD unless otherwise stated.
Data are shown for non- overlapping remission groups. That is, the group in modified Boolean remission 
does not include patients in original Boolean remission.
Bold indicates statistically significant p values (p <0.5).
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; 
RA, rheumatoid arthritis; SJC28, swollen joint count on 28 joints; TJC28, tender joint count on 28 joints; 
VAS, Visual Analogue Scale.
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